• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Generalized hypertrichosis associated with the use of interleukin 17 blockers in 2 patients with psoriasis.

作者信息

Sánchez-Dueñas Luis E, Rojano-Fritz Lizet K, García-Rodríguez Juan C

机构信息

Dermatology Department, Dermika Centro Dermatológico Láser, Guadalajara, Mexico.

Dermatology Department, DermaAdvance, Mexico City, Mexico.

出版信息

JAAD Case Rep. 2020 May 23;6(7):683-685. doi: 10.1016/j.jdcr.2020.05.023. eCollection 2020 Jul.

DOI:10.1016/j.jdcr.2020.05.023
PMID:32637523
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7327770/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb3/7327770/30e43b3e997c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb3/7327770/e637b0742f67/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb3/7327770/30e43b3e997c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb3/7327770/e637b0742f67/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfb3/7327770/30e43b3e997c/gr2.jpg

相似文献

1
Generalized hypertrichosis associated with the use of interleukin 17 blockers in 2 patients with psoriasis.2例银屑病患者使用白细胞介素17阻滞剂后出现全身性多毛症。
JAAD Case Rep. 2020 May 23;6(7):683-685. doi: 10.1016/j.jdcr.2020.05.023. eCollection 2020 Jul.
2
No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.无需改变药物类别：在银屑病中，司库奇尤单抗治疗后使用依奇珠单抗。
J Dermatolog Treat. 2019 May;30(3):216-220. doi: 10.1080/09546634.2018.1506081. Epub 2018 Sep 11.
3
A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.白细胞介素（IL）-12/23和IL-17抑制剂优特克单抗、司库奇尤单抗、依奇珠单抗、布罗达单抗、古塞库单抗和替拉珠单抗治疗中度至重度斑块状银屑病疗效和安全性的系统评价与荟萃分析
J Dermatolog Treat. 2018 Sep;29(6):569-578. doi: 10.1080/09546634.2017.1422591. Epub 2018 Mar 28.
4
Generalized hypertrichosis due to secukinumab in a patient with moderate psoriasis: A case of serendipity or zemblanity?因司库奇尤单抗致中度斑块状银屑病患者广泛性多毛症：机缘巧合还是命中注定？
Dermatol Ther. 2019 May;32(3):e12894. doi: 10.1111/dth.12894. Epub 2019 Apr 17.
5
Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.靶向白细胞介素-17 受体的单克隆抗体治疗银屑病：疗效评价。
Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5. doi: 10.1111/bjd.12025.
6
Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab.比较 ixekizumab 与 secukinumab 治疗中重度斑块状银屑病患者疗效的匹配调整间接比较。
Br J Dermatol. 2018 May;178(5):1064-1071. doi: 10.1111/bjd.16140. Epub 2018 Mar 1.
7
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.古塞库单抗与司库奇尤单抗治疗中重度银屑病（ECLIPSE）：一项 3 期随机对照临床试验的结果。
Lancet. 2019 Sep 7;394(10201):831-839. doi: 10.1016/S0140-6736(19)31773-8. Epub 2019 Aug 8.
8
IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.白细胞介素 17A 抑制剂转换 - 司库奇尤单抗治疗失败后使用依奇珠单抗的疗效。一项单中心经验。
Acta Derm Venereol. 2019 Jul 1;99(9):769-773. doi: 10.2340/00015555-3200.
9
Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.依奇珠单抗及其他美国食品药品监督管理局批准的生物制剂治疗中重度斑块型银屑病的额外应答者成本。
J Med Econ. 2017 Dec;20(12):1224-1230. doi: 10.1080/13696998.2017.1362413. Epub 2017 Aug 22.
10
Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab.司库奇尤单抗治疗失败后接受依奇珠单抗治疗的22例银屑病患者的长期随访
Dermatol Online J. 2020 Jan 15;26(1):13030/qt235408bf.

本文引用的文献

1
Are new variants of psoriasis therapy (IL-17 inhibitors) safe?银屑病治疗的新变异体（IL-17 抑制剂）安全吗？
Int J Dermatol. 2019 Dec;58(12):1360-1365. doi: 10.1111/ijd.14509. Epub 2019 Jun 13.
2
Generalized hypertrichosis due to secukinumab in a patient with moderate psoriasis: A case of serendipity or zemblanity?因司库奇尤单抗致中度斑块状银屑病患者广泛性多毛症：机缘巧合还是命中注定？
Dermatol Ther. 2019 May;32(3):e12894. doi: 10.1111/dth.12894. Epub 2019 Apr 17.
3
Excessive hair growth in a patient with psoriatic erythroderma following secukinumab administration.
司库奇尤单抗治疗后，一名银屑病红皮病患者出现毛发过度生长。
Eur J Dermatol. 2018 Aug 1;28(4):539-540. doi: 10.1684/ejd.2018.3327.
4
Repigmentation and new growth of hairs after anti-interleukin-17 therapy with secukinumab for psoriasis.使用司库奇尤单抗进行抗白细胞介素-17治疗后银屑病的色素再生和毛发新生。
JAAD Case Rep. 2018 May 7;4(5):486-488. doi: 10.1016/j.jdcr.2018.01.006. eCollection 2018 Jun.
5
Immunology of psoriasis.银屑病的免疫学
Annu Rev Immunol. 2014;32:227-55. doi: 10.1146/annurev-immunol-032713-120225.
6
The role of IL-17 in psoriasis.白细胞介素-17在银屑病中的作用。
J Dermatolog Treat. 2015 Feb;26(1):41-4. doi: 10.3109/09546634.2013.879093. Epub 2014 Feb 20.
7
Systemic therapies for psoriasis: an evidence-based update.银屑病的系统治疗：循证更新。
Am J Clin Dermatol. 2014 Jul;15(3):165-80. doi: 10.1007/s40257-014-0064-x.
8
Concomitant alopecia areata and hypertrichosis after infliximab therapy: rara avis.英夫利昔单抗治疗后并发斑秃和多毛症：罕见病例。
Acta Reumatol Port. 2013 Jan-Mar;38(1):49-50.
9
Efalizumab-induced hypertrichosis.依法利珠单抗诱发的多毛症。
Br J Dermatol. 2008 May;158(5):1158-9. doi: 10.1111/j.1365-2133.2008.08511.x. Epub 2008 Mar 20.
10
Hypertrichosis.多毛症
J Am Acad Dermatol. 2003 Feb;48(2):161-79; quiz 180-1. doi: 10.1067/mjd.2003.100.